Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0YWYJJ
ADC Name
IMGN151
Synonyms
IMGN 151; IMGN-151; IMGN151; Opugotamig olatansine
   Click to Show/Hide
Organization
ImmunoGen, Inc.
Drug Status
Phase 1
Indication
In total 5 Indication(s)
Cervical cancer
Phase 1
Clinical Trial
Endometrial cancer
Phase 1
Clinical Trial
Fallopian tube cancer
Phase 1
Clinical Trial
Ovarian cancer
Phase 1
Clinical Trial
Peritoneal cancer
Phase 1
Clinical Trial
Drug-to-Antibody Ratio
3.5
Structure
Antibody Name
Opugotamig
  Antibody Info 
Antigen Name
Folate receptor alpha (FOLR1)
  Antigen Info 
Payload Name
DM21-C
  Payload Info 
Therapeutic Target
Microtubule (MT)
  Target Info 
Linker Name
Stable cleavable peptide linker
  Linker Info 
Conjugate Type
Undisclosed
Combination Type
olatansine
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 4 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Tumor Growth Inhibition value (TGI) 
100
%
KB cells
Human papillomavirus-related endocervical adenocarcinoma
Tumor Growth Inhibition value (TGI) 
100
%
IGROV-1 cells
Ovarian endometrioid adenocarcinoma
Tumor Growth Inhibition value (TGI) 
100
%
Ishikawa cells
Endometrial adenocarcinoma
Tumor Growth Inhibition value (TGI) 
100
%
OV-90 cells
Ovarian adenocarcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 4 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) 100.00% High FOLR1 expression (FOLR1+++; IHC H-score=300)
Method Description
IMGN151 activity was characterized against cell lines and xenograft models with a wide range of FR expression and compared to IMGN853.
In Vivo Model KB CDX model
In Vitro Model Human papillomavirus-related endocervical adenocarcinoma KB cells CVCL_0372
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) 100.00% Moderate FOLR1 expression (FOLR1++; IHC H-score=140)
Method Description
IMGN151 activity was characterized against cell lines and xenograft models with a wide range of FR expression and compared to IMGN853.
In Vivo Model IGROV-1 CDX model
In Vitro Model Ovarian endometrioid adenocarcinoma IGROV-1 cells CVCL_1304
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) 100.00% Moderate FOLR1 expression (FOLR1++; IHC H-score=100)
Method Description
IMGN151 activity was characterized against cell lines and xenograft models with a wide range of FR expression and compared to IMGN853.
In Vivo Model Ishikawa CDX model
In Vitro Model Endometrial adenocarcinoma Ishikawa cells CVCL_2529
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) 100.00% Low FOLR1 expression (FOLR1+; IHC H-score=30)
Method Description
IMGN151 activity was characterized against cell lines and xenograft models with a wide range of FR expression and compared to IMGN853.
In Vivo Model OV-90 CDX model
In Vitro Model Ovarian adenocarcinoma OV-90 cells CVCL_3768
References
Ref 1 IMGN151-A next generation folate receptor alpha targeting antibody drug conjugate active against tumors with low, medium and high receptor expression. Cancer Res (2020) 80 (16_Supplement): 2890.